Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3857-3863

  Chigutsa, Emmanuel ^a   Meredith, Sandra ^a   Wiesner, Lubbe ^a   Padayatchi, Nesri ^b   Harding, Joe ^c   Moodley, Prashini ^d   Kenzie, William R Mac ^e   Weiner, Marc ^f   McIlleron, Helen ^a   Kirkpatrick, Carl M J ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c DP Marais Hospital   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f TBTC Study 30 Team   (South Africa)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ETHIONAMIDE; KANAMYCIN; LINEZOLID; OFLOXACIN; PYRAZINAMIDE; TERIZIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHARMACODYNAMICS; POPULATION PHARMACOKINETICS; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM ANALYSIS; STATISTICAL MODEL; STEADY STATE; TUBERCULOSIS;

ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84862584071     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00048-12     Document Type: Article

References (37)

1. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
2. Angeby KA, et al. 2010. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 65:946-952.
3. Chagnac A, et al. 2008. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol. Dial. Transplant. 23:3946-3952.
4. Cowley D, et al. 2008. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin. Infect. Dis. 47:1252-1259.
5. Drusano GL, et al. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
6. Duong DA, et al. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
7. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. 2002. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185:1197-1202.
8. Falagas ME, Rafailidis PI, Rosmarakis ES. 2007. Arrhythmias associated with fluoroquinolone therapy. Int. J. Antimicrob. Agents 29:374-379.
9. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
10. Ginsburg AS, et al. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis. 37:1448-1452.
11. Ginsburg AS, et al. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med. 349:1977-1978.
12. Gumbo T, et al. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
13. Hu Y, Coates AR, Mitchison DA. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657.
14. Janmahasatian S, et al. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44:1051-1065.
15. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CM, Green B. 2008. Lean body mass normalizes the effect of obesity on renal function. Br. J. Clin. Pharmacol. 65:964-965.
16. Janssen-Ortho, Inc. 2006. Floxin product monograph. Janssen-Ortho, Inc., Toronto, Canada.
17. Jesudason DR, Clifton P. 2011. Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician. Int. J. Obes. (Lond.). [Epub ahead of print.] doi:10.1038/ijo.2011. 242.
18. Ji B, Lounis N, Truffot-Pernot C, Grosset J. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
19. Lode H, et al. 1987. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob. Agents Chemother. 31:1338-1342.
20. Louw GE, et al. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276.
21. Meredith SA, Smith PJ, Norman J, Wiesner L. 2012. An LC-MS/MS method for the determination of ofloxacin in 20 μl human plasma. J. Pharm. Biomed. Anal. 58:177-181.
22. Migliori GB, et al. 2008. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 31:904-905.
23. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
24. Pillay M, Sturm AW. 2007. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45:1409-1414.
25. Preston SL, et al. 2003. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrob. Agents Chemother. 47:3393-3399.
26. Rossiter D. 2010. South African medicines formulary, 9th ed. Health and Medical Publishing Group, Rondebosch, South Africa.
27. Rustomjee R, et al. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
28. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726.
29. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann. Pharmacother. 37:1287-1298.
30. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann. Pharmacother. 37:1478-1488.
31. Shandil RK, et al. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
32. Sirgel FA, et al. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 67:1088-1093.
33. Stambaugh JJ, et al. 2002. Ofloxacin population pharmacokinetics in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 6:503-509.
34. WHO. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO, Geneva, Switzerland.
35. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of secondline antituberculosis drugs. WHO, Geneva, Switzerland.
36. Wright DH, Brown GH, Peterson ML, Rotschafer JC. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.
37. Zignol M, et al. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.